Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 69680-164

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 69680-164). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vitruvias Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine HCl Extended-release Capsules 14 mg (14mg)

Memantine Hydrochloride Extended-Release Capsules 14 mg label showing product name, strength, dosage form, and quantity of 30 capsules. Manufactured by Xiamen LP Pharmaceutical Co., Ltd. and distributed by Vitruvias Therapeutics, Inc. Label includes storage instructions and barcode with QR code.*

FDA Label Image

Memantine HCl Extended-release Capsules 28 mg (28mg)

Label for Memantine Hydrochloride Extended-Release Capsules, 28 mg strength, with 30 capsules per container. The label shows it is a prescription drug by Vitruvias Therapeutics, distributed in Auburn, AL. It includes storage recommendations and manufacturing details from Xiamen LP Pharmaceutical Co., Ltd., China. The label also displays usage instructions, barcode, and a QR code with serialization information.*

FDA Label Image

Memantine HCl Extended-release Capsules 7 mg (7mg)

Memantine Hydrochloride Extended-Release Capsules 7 mg label for oral use, containing 30 capsules. Label indicates the product is prescription-only, labeled for once daily use. Manufactured by Xiamen LP Pharmaceutical Co., Ltd., China, and distributed by Vitruvias Therapeutics, Auburn, AL. Includes storage instructions and barcode with additional serialized data in a QR code.*

FDA Label Image

Structure (Memantine001)

Chemical structure diagram of the active ingredient memantine hydrochloride, showing the molecular composition with positioning of amino, methyl groups, and hydrochloride.*

FDA Label Image

Figure 1: Time Course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Memantine002)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing Memantine Extended Release Capsules 28 mg/AChEI versus Placebo/AChEI. The graph plots clinical improvement and decline, with Memantine showing sustained improvement while Placebo shows decline after peaking around week 12.*

FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Sib Scores. (Memantine003)

A cumulative percentage of patients graph depicting SIB (Severe Impairment Battery) change from baseline. The chart compares Memantine Extended Release Capsules 28 mg with placebo, showing a curve for each group illustrating the distribution of patient responses in both treatment and placebo over a specified range of SIB change values.*

FDA Label Image

Figure 3: Time Course Of The Cibic-plus Score For Patients Completing 24 Weeks Of Treatment. (Memantine004)

A line graph showing the Clinical Dementia Rating Sum of Boxes (CDR-SB) plus score over 24 weeks of treatment, comparing Memantine Extended Release Capsules 28 mg with Placebo/ACheI. The graph depicts mean scores with error bars, indicating clinical improvement for Memantine and clinical decline for Placebo/ACheI over time.*

FDA Label Image

Figure 4: Distribution Of Cibic-plus Ratings At Week 24. (Memantine005)

A bar chart comparing the percentage of patients by CIBIC Plus Rating categories for Memantine Extended Release Capsules 28 mg and placebo. Categories range from marked improvement to marked worsening, showing patient outcome distributions for each treatment group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.